CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financial highlights
| Metric | FY 12/27/25 | FY 12/28/24 | FY 12/30/23 | FY 12/31/22 | FY 12/25/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B |
| Selling, general & administrative | $743.1M | $751.0M | $747.9M | $665.1M | $619.9M |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Interest expense | $107.0M | $126.3M | $136.7M | $59.3M | $73.9M |
| Pretax income | -$99.5M | $93.1M | $581.3M | $623.0M | $480.7M |
| Income tax expense | $42.7M | $67.8M | $100.9M | $130.4M | $81.9M |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M |
| Balance Sheet | |||||
| Cash and equivalents | $213.8M | $194.6M | $276.8M | $233.9M | $241.2M |
| Current assets | $1.4B | $1.4B | $1.6B | $1.4B | $1.3B |
| Total assets | $7.1B | $7.5B | $8.2B | $7.6B | $7.0B |
| Current liabilities | $1.1B | $994.1M | $1.1B | $1.1B | $1.0B |
| Total liabilities | $3.9B | $4.0B | $4.5B | $4.6B | $4.4B |
| Total debt | $2.1B | $2.2B | $2.6B | $2.7B | $2.7B |
| Stockholders' equity | $3.2B | $3.5B | $3.6B | $3.0B | $2.5B |
| Cash Flow Statement | |||||
| Cash from operations | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M |
| Depreciation and amortization | $403.3M | $361.7M | $314.1M | $303.9M | $265.5M |
| Stock-based compensation | $71.1M | $69.9M | $72.0M | $73.6M | $71.5M |
| Capital expenditure | $219.2M | $233.0M | $318.5M | $324.7M | $228.8M |
| Free cash flow | $518.5M | $501.6M | $365.4M | $294.9M | $532.0M |
| Share repurchases | $360.7M | $119.2M | $24.2M | $38.7M | $40.7M |
| Impairments | $165.0M | $215.0M | $0 | $0 | $0 |
Shares outstanding 48.2M · Free float 98.6%
Annual filing data through FY ended December 27, 2025; float as of July 12, 2026.